According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

The headteacher of a primary school in Australia has called the death of an 11-year-old boy in a car crash a "complete tragedy". The car veered off a road in the suburb of Hawthorn East ...

Ueda is holding an expandable toy that he uses to demonstrate how the company’s computationally designed Antibody Cages work. (GeekWire Photo / Alan Boyle) Three weeks after University of ...

The primary endpoint was the annualized bleeding ... non-inferiority to routine prophylactic factor-based therapy. The antibody’s label notes the risk of circulating blood clots ...

Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...